News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement
2
Aradhana Sarin: The CFO as a Catalyst
3
Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers
4
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
5